search

Active clinical trials for "Depressive Disorder, Major"

Results 1121-1130 of 2240

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

Depressive DisorderMajor

The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with MDD with atypical features.

Completed19 enrollment criteria

A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture

Major Depressive DisorderDepression

This is a randomized, assessor-blind, placebo controlled study in major depressive disorder (MDD) patients. Subjects receiving antidepressant drug (FLX) would be assigned to receive either 18 sham / active DCEAS for in 6 weeks. Changes in the severity of depressive symptoms over time are measured using depression rating scales. Brain glucose metabolic levels are measured using PET at baseline and endpoint. The most intriguing and expected result might be that acupuncture treated-patients may display comparable or even better outcomes and the clinical improvements by acupuncture are correlated with the restoration of the activities in the related brain regions.

Completed11 enrollment criteria

Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation

Major Depressive Disorder

The purpose of this study is to determine if repetitive transcranial magnetic stimulation (TMS) will alleviate symptoms of major depressive disorder (MDD) in pregnant women. TMS uses electromagnetic impulses to encourage neurons in the brain to communicate more effectively with one another. Effective neuron communication is thought to lead to the lessening of depressive symptoms. In this study subjects require daily TMS treatment for approximately four weeks.

Completed18 enrollment criteria

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major...

Major Depressive Disorder

The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.

Completed8 enrollment criteria

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Depressive DisorderMajor

The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented. There will be 2 study periods (5 and 9 days) and follow up will occur at least 7 days after the last dose. Screening is required within 45 days prior to the start of the study.

Completed32 enrollment criteria

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major...

Major Depressive Disorder

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.

Completed10 enrollment criteria

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder...

Major Depressive Disorder

The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.

Completed8 enrollment criteria

Effectiveness of Deep Transcranial Magnetic Stimulation in Depression

Major Depressive Disorder

We intend to investigate whether deep transcranial magnetic stimulation (DTMS), a novel brain stimulation technique, is effective for treating major depression. We hypothesize that 4 weeks of DTMS will be associated with significant improvements in depressive and anxious symptoms without significant side effects.

Completed12 enrollment criteria

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults...

Major Depressive Disorder

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? How much SPD489 should be given to patients with depression who are also taking an antidepressant? How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Completed31 enrollment criteria

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response...

Major Depressive Disorder

This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Patients will be randomized to receive once daily doses of 5 mg, 15 or 30 mg of RO4995819 or matching placebo. The anticipated time on study treatment is 6 weeks.

Completed11 enrollment criteria
1...112113114...224

Need Help? Contact our team!


We'll reach out to this number within 24 hrs